Search
BMY.US: Opdivo +Yervoy restricted to BRAF wild types by FDA despite good activity in mutants…
Implications for 2nd line non-squamous lung?
It is interesting to note that this morning’s approval of Opdivo + Yervoy in 1st line melanoma is restricted to BRAF wild type only, despite both phase II Checkmate 69 and phase III Checkmate 67 showing large improvements in PFS vs Opdivo in BRAF mutant patients. Of course current standard of care in BRAF mutants is Tafinlar+ Mekinst...
